CY1108002T1 - Παραγωγα 4-ετεροκυκλυλοσουλφοναμιδυλο-6-μεθοξυ-5- (2-μεθοξυ-φαινοξυ)-2-πυριδυλο-πυριμιδινης, παρασκευη αυτων, και χρηση τους ως ανταγωνιστες υποδοχεα ενδοθηλινης - Google Patents

Παραγωγα 4-ετεροκυκλυλοσουλφοναμιδυλο-6-μεθοξυ-5- (2-μεθοξυ-φαινοξυ)-2-πυριδυλο-πυριμιδινης, παρασκευη αυτων, και χρηση τους ως ανταγωνιστες υποδοχεα ενδοθηλινης

Info

Publication number
CY1108002T1
CY1108002T1 CY20071100324T CY071100324T CY1108002T1 CY 1108002 T1 CY1108002 T1 CY 1108002T1 CY 20071100324 T CY20071100324 T CY 20071100324T CY 071100324 T CY071100324 T CY 071100324T CY 1108002 T1 CY1108002 T1 CY 1108002T1
Authority
CY
Cyprus
Prior art keywords
methoxy
pyridyl
heterocyliculysulphonamylyl
phenoxy
producing
Prior art date
Application number
CY20071100324T
Other languages
English (en)
Inventor
Volker Breu
Philippe Coassolo
Werner Neidhart
SéBASTIEN ROUX
Peter Weiss
Original Assignee
Speedel Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Pharma Ag filed Critical Speedel Pharma Ag
Publication of CY1108002T1 publication Critical patent/CY1108002T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Οι ενώσεις του τύπου (I), όπου R1 είναι ετεροκυκλικό υπόλειμμα εκλεγόμενο από πυριδύλιο και θειαζολύλιο, και όπου το εν λόγω ετεροκυκλικό υπόλειμμα μπορεί να είναι προαιρετικώς υποκατεστημένο με κατώτερο αλκύλιο ή κατώτερο αλκενύλιο· και φαρμακευτικώς παραδεκτά άλατα αυτών, είναι αναστολείς υποδοχέων ενδοθηλίνης και μπορούν, έτσι, να χρησιμοποιηθούν για τη θεραπεία διαταραχών οι οποίες συνδέονται με μη-φυσιολογικό αγγειακό τόνο και ενδοθηλιακή δυσλειτουργία· και τα αντίστοιχα ενδιάμεσα των τύπων (III) και (V).
CY20071100324T 1999-03-03 2007-03-08 Παραγωγα 4-ετεροκυκλυλοσουλφοναμιδυλο-6-μεθοξυ-5- (2-μεθοξυ-φαινοξυ)-2-πυριδυλο-πυριμιδινης, παρασκευη αυτων, και χρηση τους ως ανταγωνιστες υποδοχεα ενδοθηλινης CY1108002T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99104306 1999-03-03
EP00909263A EP1185525B1 (en) 1999-03-03 2000-02-28 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists

Publications (1)

Publication Number Publication Date
CY1108002T1 true CY1108002T1 (el) 2013-09-04

Family

ID=8237697

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100324T CY1108002T1 (el) 1999-03-03 2007-03-08 Παραγωγα 4-ετεροκυκλυλοσουλφοναμιδυλο-6-μεθοξυ-5- (2-μεθοξυ-φαινοξυ)-2-πυριδυλο-πυριμιδινης, παρασκευη αυτων, και χρηση τους ως ανταγωνιστες υποδοχεα ενδοθηλινης

Country Status (30)

Country Link
US (2) US6417360B1 (el)
EP (1) EP1185525B1 (el)
JP (1) JP3488203B2 (el)
KR (1) KR100478798B1 (el)
CN (1) CN1342158B (el)
AR (1) AR044720A1 (el)
AT (1) ATE353325T1 (el)
AU (1) AU756738B2 (el)
BR (1) BR0008717A (el)
CA (1) CA2364906C (el)
CY (1) CY1108002T1 (el)
CZ (1) CZ300324B6 (el)
DE (1) DE60033280T2 (el)
DK (1) DK1185525T3 (el)
ES (1) ES2280198T3 (el)
HK (1) HK1044943B (el)
HR (1) HRP20010630B1 (el)
HU (1) HUP0200080A3 (el)
ID (1) ID30484A (el)
IL (1) IL145051A0 (el)
MA (1) MA26776A1 (el)
NO (1) NO320809B1 (el)
NZ (1) NZ513671A (el)
PL (1) PL198815B1 (el)
PT (1) PT1185525E (el)
RS (1) RS50109B (el)
RU (1) RU2201928C1 (el)
TR (1) TR200102562T2 (el)
WO (1) WO2000052007A1 (el)
ZA (1) ZA200107157B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US20020184047A1 (en) * 2001-04-03 2002-12-05 Plotnick Michael A. Universal ad queue
EP1454625A1 (en) * 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies
EP1595880A1 (en) * 2004-05-13 2005-11-16 Speedel Pharma AG Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists
BRPI0615794A2 (pt) * 2005-09-12 2011-05-24 Speedel Pharma Ag piridilsulfonamidil-pirimidinas para a prevenção de falha de enxerto de vaso sangüìneo
BRPI0709950A2 (pt) * 2006-04-13 2011-08-02 Actelion Pharmaceuticals Ltd uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin
EP1938812A1 (en) * 2006-12-22 2008-07-02 Speedel Pharma AG Pharmaceutical composition using aliskiren and avosentan
WO2010011868A2 (en) * 2008-07-23 2010-01-28 Auspex Pharmaceuticals Pyridine sulfonamide modulators of endothelin-a-receptor
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
KR101936054B1 (ko) 2017-06-23 2019-01-11 한국과학기술연구원 항염증 활성을 가지는 6-페녹시피리미딘 유도체, 이의 제조방법 및 이를 활성성분으로 하는 약학 조성물
WO2023111299A1 (en) 2021-12-17 2023-06-22 Idorsia Pharmaceuticals Ltd Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837708A (en) 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
CA2162630C (en) 1994-11-25 2007-05-01 Volker Breu Sulfonamides
CN1064965C (zh) * 1994-11-25 2001-04-25 弗·哈夫曼-拉罗切有限公司 新的磺酰胺类化合物及其作为药物的用途
TW313568B (el) * 1994-12-20 1997-08-21 Hoffmann La Roche
EP0897914B1 (en) 1997-08-19 2004-05-26 F. Hoffmann-La Roche Ag Process for the preparation of 2,5-disubstitued pyridines
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides

Also Published As

Publication number Publication date
RU2201928C1 (ru) 2003-04-10
NO320809B1 (no) 2006-01-30
EP1185525B1 (en) 2007-02-07
KR20010102480A (ko) 2001-11-15
ATE353325T1 (de) 2007-02-15
MA26776A1 (fr) 2004-12-20
JP3488203B2 (ja) 2004-01-19
TR200102562T2 (tr) 2002-02-21
US6417360B1 (en) 2002-07-09
CA2364906C (en) 2006-01-10
KR100478798B1 (ko) 2005-03-24
PL198815B1 (pl) 2008-07-31
CZ20013108A3 (cs) 2002-02-13
HK1044943B (zh) 2013-03-22
US20020137933A1 (en) 2002-09-26
IL145051A0 (en) 2002-06-30
PL351794A1 (en) 2003-06-16
EP1185525A1 (en) 2002-03-13
AU3161100A (en) 2000-09-21
NO20014224D0 (no) 2001-08-31
HUP0200080A3 (en) 2003-01-28
CA2364906A1 (en) 2000-09-08
HRP20010630A2 (en) 2002-08-31
HRP20010630B1 (en) 2010-08-31
DK1185525T3 (da) 2007-06-04
HUP0200080A2 (en) 2002-06-29
ID30484A (id) 2001-12-13
AU756738B2 (en) 2003-01-23
ZA200107157B (en) 2002-11-29
AR044720A1 (es) 2005-10-05
PT1185525E (pt) 2007-05-31
YU62801A (sh) 2004-07-15
HK1044943A1 (el) 2002-11-08
US6521631B2 (en) 2003-02-18
WO2000052007A1 (en) 2000-09-08
BR0008717A (pt) 2001-12-26
RU2001126348A (ru) 2004-03-20
CZ300324B6 (cs) 2009-04-22
CN1342158B (zh) 2012-06-06
NZ513671A (en) 2003-04-29
NO20014224L (no) 2001-08-31
DE60033280T2 (de) 2007-11-22
RS50109B (sr) 2009-03-25
DE60033280D1 (de) 2007-03-22
ES2280198T3 (es) 2007-09-16
CN1342158A (zh) 2002-03-27
JP2002538156A (ja) 2002-11-12

Similar Documents

Publication Publication Date Title
CY1108002T1 (el) Παραγωγα 4-ετεροκυκλυλοσουλφοναμιδυλο-6-μεθοξυ-5- (2-μεθοξυ-φαινοξυ)-2-πυριδυλο-πυριμιδινης, παρασκευη αυτων, και χρηση τους ως ανταγωνιστες υποδοχεα ενδοθηλινης
NO20020823D0 (no) Heterosykliske forbindelser og deres anvendelse som metabotrofisk glutamatreseptor-antagonister
IS2754B (is) @@oxó@@@pýrrólidín@afleiða@og@lyfjafræðileg@notkun@hennar
CY1112991T1 (el) ΠΑΡΑΓΩΓΑ ΙΝΔΟΛΗΣ Ή ΒΕΝΖΙΜΙΔΑΖΟΛΗΣ ΓΙΑ ΤΗ ΡΥΘΜΙΣΗ ΤΗΣ ΙκΒ ΚΙΝΑΣΗΣ ΚΑΙ ΕΝΔΙΑΜΕΣΑ ΠΡΟΪΟΝΤΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ
NO986055D0 (no) Nye heterocykliske forbindelser, deres fremstilling, farmas÷ytiske preparat
NO20060219L (no) Forbindelser
CY1105784T1 (el) Εκδοχα της πιπepαζινυλακυλπιπepιδινης η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη
LU92113I2 (fr) Perampanel et ses dérivés pharmaceutiquement acceptables (FYCOMPA)
DK0923554T3 (da) N-Benzylpiperidin- og tetrahydropyridinderivater
YU47481B (sh) Derivati beta-laktama i postupak za njihovo dobijanje
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
YU19890A (sh) Derivati tetrahidrobenzimidazola i postupak za njihovo dobijanje
PT1064281E (pt) Derivados de distamicina benzo-heterociclicos processo para os preparar e a sua utilizacao como agentes antitumorais
EA200200358A1 (ru) Глюкопиранозидные конъюгаты 2-(4-гидроксифенил)-1-[4-(2-амин-1-илэтокси)бензил]-1h-индол-5-олов
ATE360612T1 (de) In 4-stellung substituierte piperidinderivate
CY1105158T1 (el) Εκδοχα πυριδοϊνδολονης που φερει υποκαταστατη στο -3 μια ετepοκυκλικη ομαδα, η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη
AR027035A1 (es) Pirroles sustituidos
CY1107794T1 (el) Νeα μeθοδος παρασκευhς παραγωγων εποθιλονης
ATE473234T1 (de) Trh-ähnliche peptidderivate als inhibitoren des trh-abbauenden ektoenzyms
DK369289A (da) Anvendelse af imidazopyrazolderivater som analgetica og antiinflammatoriske midler
NO982549L (no) 5-naftalen-1-yl-1,3-dioksan-derivater, fremstilling og terapeutisk anvendelse derav
CY1108404T1 (el) Βητα-λακταμες για θεραπεια διαταραχων του κνς
AR008920A1 (es) Proceso para la preparacion de los derivados de 2-amino-2-imidaxolina, guanidina, y 2-amino-3,4,5,6-tetrahidropiridimina
FR2823749A1 (fr) Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant
TR199801735A2 (xx) 2-(arilfenil)amino-imidazolin türevleri.